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Abstract
Stem cells hold enormous promise for regenerative 
medicine as well as for engineering of model systems to 
study diseases and develop new drugs. The discovery of 
protocols that allow for generating induced pluripotent 
stem cells (IPSCs) from somatic cells has brought this 
promise steps closer to reality. However, as somatic 
cells might have accumulated various chromosomal 
abnormalities, including aneuploidies throughout their 
lives, the resulting IPSCs might no longer carry the 
perfect blueprint for the tissue to be generated, or 
worse, become at risk of adopting a malignant fate. In 
this review, we discuss the contribution of aneuploidy to 
healthy tissues and how aneuploidy can lead to disease. 
Furthermore, we review the differences between how 
somatic cells and stem cells respond to aneuploidy.
Key words: Chromosomal instability; Aneuploidy; 
Embryonic stem cells; Induced pluripotent stem cells; 
Mesenchymal stem cells
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Stem cells hold great therapeutic promise for 
regenerative medicine, especially with new protocols 
that can create induced pluripotent stem cells from 
terminally differentiated cells. However, somatic cells 
and stem cells cope differently with genomic instability. 
Therefore, it will be of the utmost importance to assess 
genomic integrity when preparing stem cell cultures for 
future therapy.
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INTRODUCTION
Chromosomal instability (CIN) is a process that leads 
to cells with unbalanced genomes, containing structural 
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abnormalities (i.e., structural CIN leading to amplification, 
deletions, translocations), numerical abnormalities 
(i.e., numerical CIN), or both. Numerical CIN leads to 
aneuploidy, a state in which cells have abnormal numbers 
of whole chromosomes. While the majority of all cancers 
are aneuploid[1], aneuploidy itself appears to act anti-
proliferative in non-transformed cells, suggesting that 
cancer cells somehow have adjusted to the adverse 
effects of aneuploidy[2,3]. Emerging evidence is indicating 
that aneuploidy in somatic cells increases with age and 
might even contribute to natural ageing[4-8]. In fact, we are 
only beginning to understand how our somatic cells and 
stem cells cope with loss of genomic integrity. As future 
regenerative medicine-based therapies will likely make 
use of induced pluripotent stem cells (iPSCs) derived from 
somatic (aged) patient’s cells, aneuploidy will become 
an important parameter to test for when assessing the 
quality of the transplanted cells. Furthermore, much is 
still unknown regarding the effects aneuploidy on the 
functionality of both somatic stem cells and iPSCs. In this 
review, we will discuss the impact of aneuploidy on healthy 
stem cells, how aneuploidy can lead to disease, and how 
stem cells cope with genomic instability.
ANEUPLOIDY IN HEALTHY TISSUES
Even though systemic aneuploidies or high CIN rates 
are poorly tolerated during development, various lines 
of evidence indicate that some of our tissues can cope 
remarkably well with aneuploidy[9] and even show 
aneuploidy under “normal” conditions[4]. Two tissues that 
have been associated with increased aneuploidy frequencies 
are brain and liver. 
Aneuploidy in the brain
Aneuploidy in mature brain can affect both the neuronal 
and non-neuronal populations of the cortex[10,11], and 
is thought to originate in ventricular zone progenitors 
that encounter a variety of cell division defects during 
embryogenesis[12,13]. While the most common aneuploid 
event in progenitors is the loss of a single chromosome, 
progenitors with up to 5 chromosome losses have been 
reported. Based on this and other work, cumulatively, 
10% of neurons in a healthy brain are estimated to be 
aneuploid[14], but the role and fate of these cells remains 
unclear. For more extensive review see Bushman et al[15].
The precise contribution of aneuploidy to the healthy 
human brain remains unclear. One possible explanation 
is that aneuploidy actually serves a function and is part 
of a “normal” process during brain development resulting 
in heterogeneous neuronal and glial populations that 
contribute to the wide functions that neurons can have[16]. 
An alternative explanation however is that aneuploidy 
rates have been overestimated due to technical 
limitations of the protocols used to quantify aneuploidy 
in neurons (in most cases interphase FISH)[17], which 
was reinforced by recent studies that used single cell 
next generation sequencing to determine chromosome 
copy numbers in adult brains[14,18-20]. Aneuploidy in the 
brain has furthermore been linked to various pathologies 
such as Alzheimer’s disease (AD) (increased trisomy of 
chromosome 21), schizophrenia, and autism[21,22]. Further 
quantification of aneuploidy in the (diseased) human brain 
is needed to resolve these conflicting observations.
Aneuploidy in the liver
Roughly half of the hepatocytes in an adult liver are 
polyploid or aneuploid[23]. Interestingly, liver regeneration 
has been attributed to proliferation of mature hepato-
cytes, but not liver stem cells[24]. This is in line with 
other observations that stem cells tolerate aneuploidy 
poorly[4,9]. The aneuploidization and polyploidization of 
hepatocytes has been suggested to contribute to a great 
variety of hepatocyte genotypes that could help the 
liver adapt to different insults and chronic stressors[23]. 
While single cell next generation sequencing failed to 
detect aneuploidy in adult neurons, it did confirm the 
polyploidy and aneuploidy rates previously measured in 
hepatocytes[18], further emphasizing the importance of 
increased efforts to quantify aneuploidy in various tissues 
using several techniques.
ANEUPLOIDY IN HUMAN PATHOLOGIES
Stem cells and ageing
Functional exhaustion of adult stem cells is an important 
contributing factor to natural ageing, as stem cells are 
essential for tissue maintenance, especially in tissues 
that have a high turnover rate, such as the intestinal 
wall and the skin[25]. Indeed, ageing coincides with a 
functional decline of stem cell function in various organs, 
even though this is not always accompanied by reduced 
stem cell numbers. For example, in humans and some 
mouse strains the number of hematopoietic stem cells 
even increases during ageing[26-28], but their potential to 
differentiate decreases[28]. However, whether increased 
aneuploidy rates as observed in ageing tissues[8,29] 
contribute to stem cells exhaustion needs further testing. 
There are several syndromes that are caused by systemic 
aneuploidy that exhibit also premature ageing features, 
such as Down’s syndrome (DS) or Edward’s syndrome. 
However, how the systemic aneuploidy in these patients 
impacts stem cell integrity and stem cell numbers requires 
further investigation.
Stable systemic aneuploidy: DS
The most well known condition linked to systemic 
aneuploidy is DS. This syndrome, caused by a systemic 
gain of chromosome 21 (trisomy 21), is associated 
with developmental and cognitive defects and affects 
about 1 in 700 individuals[30]. In line with a role of 
aneuploidy in natural ageing[8], DS is associated with an 
earlier onset of aging-related pathologies such as AD, 
and an increased incidence of cancer[31]. One proposed 
driver of the accelerated ageing phenotype in DS is 
the observed overexpression of CDKN2A, as a result of 
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epigenetic remodulation in various cell lineages including 
hematopoietic stem cells, mammary epithelium, fibroblasts 
and neural progenitors cells[32]. Enhanced CDKN2A 
expression is associated with senescence and stem 
cell self-renewal defects, further emphasizing the link 
between aneuploidy and ageing.
STEM CELLS AND CIN
Stem cell biology is a rapidly developing field recently 
revolutionized through the discovery for protocols to revert 
terminally differentiated cells back into a pluripotent state 
(IPSCs)[33]. Stem cells hold great therapeutic promise 
for the treatment of a large number of diseases and are 
defined as cell lineages that have 3 cardinal features: (1) 
self-renewal through asymmetric cell division yielding one 
stem cell and one differentiated cell or symmetric division 
yielding two stem cells; (2) the capacity to produce 
multiple cell lineages; and (3) the potential to proliferate 
extensively[34,35]. We are only beginning to understand 
how to isolate and maintain stem cells in tissue culture 
and how to differentiate them into specific tissues, all of 
which are crucially important to exploit stem cells in future 
therapies[36].
Stem cell potency
Stem cells can be subdivided in two subtypes that differ 
in their differentiation potential or potency: (1) Pluripotent 
stem cells: Embryonic stem cells (ESCs) are pluripotent, 
which means that they can form any embryonic tissue, 
embryonic therefore can form a complete and viable 
organism when injected into a blastocyst. Mouse ESC 
culture has revolutionized biology as it allowed for making 
transgenic and knockout mice[37,38]; Pluripotent stem cells 
can form any of the three germ layers of an embryo. 
The recent discovery of protocols to induce pluripotency 
in differentiated cells, yielding IPSCs[33] has propelled 
the stem cell field as a whole and made this stem cell 
subtype the current central tool in stem cell research, as, 
in theory, iPSC protocols would allow us to make any cell 
type from any patient’s somatic cell, overcoming graft 
versus host disease and omitting the ethical concerns of 
human ESCs; and (2) The second subtype of stem cells 
are multipotent, somatic or adult stem cells. These stem 
cells that can form a number of lineages, typically within 
one tissue type. Examples of somatic stem cells are 
neural stem cells, mammary stem cells or hematopoietic 
stem cells. In many cases somatic stem cells produce 
unipotent proliferative cells or transit amplifying cells, e.g., 
through asymmetric stem cell division These cells can 
still replicate, but only form one cell lineage before cells 
terminally differentiate and exit the cell cycle[39] and are 
therefore not considered to be genuine stem cells.
HOW CAN STEM CELLS RESPOND TO 
ANEUPLOIDY?
Because of their important role in development and 
tissue maintenance, stem cells have to safeguard their 
genome integrity. Any genetic alteration that may occur 
in a dividing stem cell will be inherited by the entire 
lineage emerging from this single stem cell and thus 
give rise to severe developmental defects or pathologies. 
Genomic integrity maintenance in stem cells is not only 
important for proper embryonic development and adult 
tissue homeostasis, but also an essential requirement 
for the use of stem cells in regenerative medicine and 
research. This is particularly true for mesenchymal 
stem cells (MSCs), that are already used in therapy. 
Importantly, both embryonic and somatic stem cells 
have developed ways to prevent the negative effects of 
mutations and aneuploidies resulting in an increased DNA 
damage response in stem cells as compared to somatic 
cells, thus preventing structural CIN[40].
DNA damage repair systems in stem cells
One way stem cells accomplish an increased DNA 
damage response is by increasing the expression of 
genes involved in DNA repair resulting in increased 
efficiency in repairing DNA lesions, when compared 
to differentiated cells[40]. The most dangerous form of 
DNA damage is the formation of DNA double strand 
breaks (DSBs). These can arise from replication stress, 
reactive oxygen species (ROS), mutagens and other 
DNA damaging events. To repair DSBs, cells employ two 
main DNA repair systems: Non-homologous end joining 
(NHEJ) and homologous recombination (HR). NHEJ is an 
error-prone form of repair taking place in the G1 phase 
of the cell cycle in which the sequence flanking the break 
point is resected followed by blunt end ligation of the 
DNA ends, which by definition results in small deletions 
in the DNA sequence. In contrast, HR utilizes the sister 
chromatid as a repair template to fully repair the DSB, 
and can therefore only occur when sister chromatids 
are available, in the G2 phase of the cell cycle. Another 
way by which stem cells maintain genomic fidelity is 
by their predominant use of HR to repair DSBs, while 
differentiated (non-proliferating) cells can only use NHEJ, 
as the latter have exited the cell cycle and therefore 
have no “access” to duplicated sister chromatids[41,42]. 
Therefore, the preferred use of HR to repair DNA DSBs 
combined with more sensitive DNA damage signaling 
helps stem cells to maintain genomic integrity.
The safe way out: Apoptosis and differentiation
An alternative method to prevent daughter cells from 
inheriting genomic aberrations is by eliminating the 
aberrant stem cells from the stem cell pool. This can be 
done through apoptosis, removing the cell altogether, or 
by differentiating the compromised stem cell in order to 
avoid further cell divisions. Indeed, when encountering 
DNA damage, stem cells activate the p53 pathway to 
mobilize the DNA repair machinery. When damage 
remains unrepaired, p53 activity promotes apoptosis. 
While apoptosis is the main response to DNA damage 
in stem cells, induction of p53 in human stem cells can 
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also result in spontaneous differentiation[43], however, 
which factors determine the switch between these two 
choices are so far unclear. 
This is exemplified further by the ways by which 
different stem cell types respond to DNA damage. For 
example, hematopoietic stem cells (HSCs) enhance DNA 
repair and stem cell maintenance, and prevent apoptosis 
to avoid depletion of the HSC pool. Intestinal stem cells on 
the other hand favor increased cell death and melanocytes 
respond by terminal differentiation[44]. Therefore, diffe-
rent responses to DNA damage in different stem cell 
populations will yield different effects on the integrity of 
the stem cell pool and their downstream potencies.
STEM CELLS COPE POORLY WITH 
NUMERICAL CIN
Numerical CIN and the resulting aneuploidy is detrimental 
for embryonic development, evidenced by early 
embryonic death observed in mouse models in which high 
grade numerical CIN was provoked systemically, see for 
extensive review[45-47]. While these observations led to the 
prevailing view that high grade numerical CIN is never 
tolerated, more recent observations are nuancing this 
view. For instance, when numerical CIN was provoked in a 
tissue specific fashion, in mouse epidermis, epidermal hair 
follicle stem cells were rapidly depleted, while the more 
committed transit amplifying (unipotent) cells tolerated 
the resulting high grade aneuploidy remarkably well[9]. 
Furthermore, while aneuploid cells seem to accumulate in 
various somatic cell types in the ageing mouse, aneuploidy 
in stem cell linages in the same mice remains rare, further 
indicating that stem cells are well protected against (or 
ultra sensitive to) numerical chromosome abnormalities[4]. 
However, even though these observations are suggestive 
of an aneuploidy checkpoint in stem cells, more work is 
needed to reveal if this checkpoint does exist and if so, 
how this checkpoint operates.
DO CULTURE CONDITIONS IMPACT 
STEM CELL GENOMIC INTEGRITY?
As stem cells are typically isolated in small quantities and 
iPSC protocols are still quite inefficient, stem cells are 
exposed to a period of tissue culture stress that can yield 
(further) CIN. While the majority of such alterations will 
be negatively selected and therefore disappear within a 
few passages, some genetic alterations could result in 
proliferative advantages and outcompete the “normal” 
stem cells, a process known as “culture adaptation”[48] 
resulting in late passage cultures that grow better and 
show better plating efficiencies[49].
Frequently reported chromosome aberrations in stem 
cells
Various cytogenetic abnormalities have been reported in 
cultured ESCs, with varying frequencies in different cell 
strains. The most common abnormality reported in murine 
ESCs is trisomy of chromosome 8 (Table 1). Trisomies of 
chromosome 12, 14 and 17 are most frequently observed 
in human ESCs[50], but not necessarily within the same 
ES cell line. Further studies that investigated the genomic 
integrity of > 150 human ES cell lines and 220 iPSC 
lines found that, while the majority of the stem cell lines 
were euploid, approximately 12%-13% of human ES 
cell lines and similar fractions of iPSC lines showed whole 
chromosome abnormalities[49,51].
Notably in ESC culture, chromosomal abnormalities 
increased with prolonged culturing as late passage 
cultures had approximately twice as many aberrations, 
which typically involved gain of chromosomes[49]. In 
line with culture adaptation, chromosome aberrations 
were non-random with 60% of the aneuploid stem cell 
cultures showing abnormalities for chromosomes 1, 12, 
17 and/or 20 (Table 1)[49]. Chromosome 12 gain has been 
observed by others as well[52,53] and although selection for 
chromosome 12 is likely to be driven by multiple genes, 
it is tempting to speculate that NANOG is a key driver for 
this commonly observed trisomy in stem cell cultures, 
possibly together with the pluripotency related DPPA3 and 
GDF3, and the cell cycle regulator CCND2. Furthermore, 
the oncogene KRAS is also located on chromosome 
12[49,54]. Importantly, culture conditions appear to also 
have an important impact on genomic integrity of stem 
cell cultures, for instance the use of fetal bovine serum 
as growth supplement results in increased chromosomal 
abnormalities[55]. Last, but certainly not least important, 
iPS cells are typically derived from somatic (differentiated 
cells) that appear to tolerate aneuploidy much better 
than previously anticipated[9] and therefore the founder 
cells could already have been aneuploid to start out 
with. Aneuploidies in these founder cells might lower 
IPSC protocol’s efficiency if the induced stem cells do not 
tolerate the aneuploidies. Even worse, when aneuploidies 
in the founder cells are subtle, the aneuploidies could be 
maintained in the resulting IPSC clones.
As MSCs are frequently used in therapy, their genomic 
stability is routinely assessed. The most commonly 
reported type of aberration in MSCs several passages after 
cell expansion is tetraploidization, observed in 6 out 21 
patient-derived cell lines[56]. Tetraploidy was observed only 
in a minority of examined metaphases (approximately 1 in 
20-30 per cell line), and whether the contribution of these 
tetraploid cells will have significant consequences in vivo 
needs further investigation. Other reported aberrations 
include a preferential loss of chromosome 13 in later 
passages of the human MSC line UE6E7T-3 (Table 1)[57], 
Table 1  Reported chromosomal aberrations in different stem 
cell types
Species Stem cell type Chromosomal aberration
Human Cultured embryonic stem cells +1, +12, +14, +17, +20
Mesenchymal stem cells 4N, -13
+4, +5, +10, +X
Mouse Cultured embryonic stem cells +8
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and the emergence of clonal trisomies for chromosomes 4, 
5, 10, and X in a male patient-derived MSC[58]. Therefore, 
while cytogenetic aberrations are widely reported for 
MSCs, their ultimate effect on MSC proliferation and 
potency in vivo are less well understood. This also 
holds true for other stem cell populations in vivo. Novel 
karyotyping methods (for extensive review see Bakker et 
al[17]) that circumvent the limitations of existing techniques 
will be instrumental in resolving both the incidence and 
effects of aneuploidy in adult stem cells in various different 
tissues.
CONCLUSION
Stem cells are the origin of tissue homeostasis and 
therefore crucially rely on genomic integrity. Fortunately, 
stem cells appear to be much more sensitive to DNA 
damage and aneuploidy than their differentiated counter-
parts[9,40-42]. However, as IPSC protocols force terminally 
differentiated cells back into the cell cycle, cells might 
accumulate mutations in the process of becoming 
pluripotent, or even harbor chromosomal abnormalities 
before dedifferentiation starts. Therefore, as IPSC 
protocols are becoming the new standard in regenerative 
medicine, it will be of the utmost importance to develop 
sequencing pipelines that can ensure chromosomal 
fidelity of the engineered IPSCs or IPSC-derived tissues. 
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